Edition 1/2019 : The evolving landscape of Biosimilars and it”s impact on the public procurement and Tendering environment
Highpoint, an IQVIA company, has conducted various analysis to assess the impact of tenders for biosimilars and observed recent market trends as well as manufacturer behaviors to capture the subtle changes. Our findings translate into a comprehensive view on how companies could improve their bidding and tender strategy to succeed in this space. lastly, we provide our outlook on this topic emphasizing the importance for all stakeholders to find the right balance between cost containment for payers and sustainability for manufacturers to ensure that ultimately, patients and physicians will have multiple treatment options available.
The EPP® Thought Leadership Series provide insights from pricing leaders around the globe. When a new insight breaks, these pricing leaders already think of the unanswered questions and the story behind the story. These people want to inspire you to act - to take the next step in your journey. With these series, we help to take the right actions.
EPP Prime+ Required to access this resource
Join EPP Prime+ now and get direct access to the best resources, weekly updated with new content, webinars, dynamic talks, tools from the EPP Community.
Subscribe your team and benefit from important group discounts